Abstract. Survivin and its splice variants DEx3 and 2B are involved in pathogenesis of numerous types of cancer. Proliferating cell nuclear antigen (PCNA) level correlates with cellular proliferation. The present study aimed to analyze the potential utility of survivin and its splice variants DEx3 and 2B as biomarkers for thyroid cancer. PCNA, survivin and its splice variants DEx3 and 2B expressions were analyzed in 22 tissue samples (15 thyroid cancers and 7 benign lesions) by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry (IHC). There was significantly higher staining for survivin (P=0.019), survivin DEx3 (P=0.001), survivin 2B (P=0.0149) and PCNA (P=0.0237) in thyroid malignant tumors when compared with benign lesions. The receiver operating characteristics curve analysis has shown that the cut-off points of survivin IHC expression >2 [sensitivity 46.7%; specificity 100%; area under curve (AUC) 0.810; P= 0.0005] and survivin DEx3 IHC expression >0 (sensitivity 86.7%; specificity 100%; AUC 0.933; P<0.0001) were the best predictors of thyroid malignancy. Additionally, PCNA staining >1 (sensitivity 93.3%; specificity 71.4%; AUC 0.790; P=0.0243) and survivin 2B >2 (sensitivity 46.7%; specificity 100%; AUC 0.824; P= 0.0002) were the best predictors of thyroid cancer. In conclusion, the present study exhibited that survivin DEx3 expression has high specificity and sensitivity for discrimination between benign thyroid lesions and cancers. Survivin DEx3 may be considered a biological marker of thyroid malignancy and therefore applied in clinical practice.
IntroductionThe incidence of thyroid cancer in developed countries has increased (1). Histopathological examination remains the gold standard for the diagnosis and classification of thyroid lesions excised during surgery (2). In addition, molecular markers of thyroid cancers may be used as diagnostic and even prognostic tools (3,4). Certain markers may also be targets for non-conventional therapy.Survivin, a protein belonging to the family of apoptosis inhibitors, is involved in cell-cycle regulation and proliferation (5,6). Survivin overexpression has been observed in types of endocrine cancer including differentiated and medullary thyroid cancer, while was not upregulated in benign pituitary adenoma (7-16). However, survivin has not been proven to discriminate between thyroid follicular cancer and adenoma (17,18). The two survivin splice variants 2B and DEx3 demonstrate different biological properties. Survivin 2B is involved in apoptosis activation. By contrast, anti-apoptotic survivin DEx3 is suggested to be associated with tumor aggressiveness, advanced stage and poor prognosis in numerous types of cancer (5). We have previously reported survivin and its DEx3 mRNA variant overexpression in thyroid cancer (19,20).Another nuclear protein, proliferating cell nuclear antigen (PCNA), is also involved in replication, so its level correlates with cellular proliferation (21).The aims of the present study were to confirm the findin...